文献速递临床试验与 GCP流行病学与生物统计

利用灌注影像将溶栓时间窗延长至4.5-9小时及醒后卒中:个体患者数据的系统综述与Meta分析

Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.
PubMed 文献 · Lancet · 2019-05-22

该系统综述与Meta分析纳入EXTEND、ECASS4-EXTEND和EPITHET三项随机试验的414例缺血性卒中患者,比较阿替普酶与安慰剂在发病4.5-9小时或醒后卒中且灌注影像提示可挽救脑组织患者中的疗效。阿替普酶组3个月极佳功能结局(mRS 0-1)比例高于安慰剂组(36% vs 29%,校正OR 1.86,95%CI 1.15-2.99,p=0.011),但症状性颅内出血发生率更高(5% vs <1%,校正OR 9.7,95%CI 1.23-76.55,p=0.031),死亡无显著差异。

要点

  • 灌注影像筛选下,发病4.5-9小时或醒后卒中患者接受阿替普酶3个月极佳功能结局优于安慰剂。
  • 阿替普酶组症状性颅内出血发生率高于安慰剂组(5% vs <1%)。
  • 两组死亡无显著差异(14% vs 9%,校正OR 1.55,95%CI 0.81-2.96,p=0.66)。

核心结论

  • 发病4.5-9小时或醒后卒中且灌注影像提示可挽救脑组织的缺血性卒中患者,接受阿替普酶治疗的功能结局优于安慰剂。
  • 阿替普酶组症状性颅内出血发生率更高,但该增加未抵消溶栓的总体净获益。

研究设计与样本

  • 系统综述与个体患者数据Meta分析,检索PubMed 2006年1月1日至2019年3月1日发表的英文随机试验,并检索ClinicalTrials.gov。
  • 纳入标准为年龄≥18岁、发病超过4.5小时或醒后卒中的缺血性卒中患者,接受灌注-弥散MRI或CT灌注成像,比较阿替普酶与安慰剂。
  • 共纳入EXTEND、ECASS4-EXTEND和EPITHET三项试验的414例患者,阿替普酶组213例(51%),安慰剂组201例(49%)。
  • 主要结局为3个月极佳功能结局(mRS 0-1),校正基线年龄和临床严重程度;安全性结局为死亡和症状性颅内出血。
  • 采用混合效应logistic回归模型计算校正基线年龄和NIHSS评分的比值比(OR)。研究注册号PROSPERO CRD42019128036。

主要发现

  • 阿替普酶组211例和安慰剂组199例有3个月mRS评估数据并纳入主要结局分析。
  • 阿替普酶组76/211例(36%)与安慰剂组58/199例(29%)达到3个月极佳功能结局(校正OR 1.86,95%CI 1.15-2.99,p=0.011)。
  • 阿替普酶组症状性颅内出血10/213例(5%)vs 安慰剂组1/201例(<1%)(校正OR 9.7,95%CI 1.23-76.55,p=0.031)。
  • 阿替普酶组死亡29/213例(14%)vs 安慰剂组18/201例(9%)(校正OR 1.55,95%CI 0.81-2.96,p=0.66)。

临床怎么用

  • 原文结论指出,发病4.5-9小时或醒后卒中且灌注影像提示可挽救脑组织的缺血性卒中患者,接受阿替普酶治疗的功能结局优于安慰剂。
  • 原文结论指出,阿替普酶组症状性颅内出血发生率更高,但该增加未抵消溶栓的总体净获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stroke thrombolysis with alteplase is currently recommended 0-4·5 h after stroke onset. We aimed to determine whether perfusion imaging can identify patients with salvageable brain tissue with symptoms 4·5 h or more from stroke onset or with symptoms on waking who might benefit from thrombolysis. METHODS: In this systematic review and meta-analysis of individual patient data, we searched PubMed for randomised trials published in English between Jan 1, 2006, and March 1, 2019. We also reviewed the reference list of a previous systematic review of thrombolysis and searched ClinicalTrials.gov for interventional studies of ischaemic stroke. Studies of alteplase versus placebo in patients (aged ≥18 years) with ischaemic stroke treated more than 4·5 h after onset, or with wake-up stroke, who were imaged with perfusion-diffusion MRI or CT perfusion were eligible for inclusion. The primary outcome was excellent functional outcome (modified Rankin Scale [mRS] score 0-1) at 3 months, adjusted for baseline age and clinical severity. Safety outcomes were death and symptomatic intracerebral haemorrhage. We calculated odds ratios, adjusted for baseline age and National Institutes of Health Stroke Scale score, using mixed-effects logistic regression models. This study is registered with PROSPERO, number CRD42019128036. FINDINGS: We identified three trials that met eligibility criteria: EXTEND, ECASS4-EXTEND, and EPITHET. Of the 414 patients included in the three trials, 213 (51%) were assigned to receive alteplase and 201 (49%) were assigned to receive placebo. Overall, 211 patients in the alteplase group and 199 patients in the placebo group had mRS assessment data at 3 months and thus were included in the analysis of the primary outcome. 76 (36%) of 211 patients in the alteplase group and 58 (29%) of 199 patients in the placebo group had achieved excellent functional outcome at 3 months (adjusted odds ratio [OR] 1·86, 95% CI 1·15-2·99, p=0·011). Symptomatic intracerebral haemorrhage was more common in the alteplase group than the placebo group (ten [5%] of 213 patients vs one [<1%] of 201 patients in the placebo group; adjusted OR 9·7, 95% CI 1·23-76·55, p=0·031). 29 (14%) of 213 patients in the alteplase group and 18 (9%) of 201 patients in the placebo group died (adjusted OR 1·55, 0·81-2·96, p=0·66). INTERPRETATION: Patients with ischaemic stroke 4·5-9 h from stroke onset or wake-up stroke with salvageable brain tissue who were treated with alteplase achieved better functional outcomes than did patients given placebo. The rate of symptomatic intracerebral haemorrhage was higher with alteplase, but this increase did not negate the overall net benefit of thrombolysis. FUNDING: None.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Campbell BCV, Ma H, Ringleb PA, et al. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet. 2019. PMID: 31128925. doi:10.1016/S0140-6736(19)31053-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。